Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Well Pharmaceutical Group Co has the GF Score of 81, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Nanjing Well Pharmaceutical Group Co (SHSE:603351) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Nanjing Well Pharmaceutical Group Co GF Score Related Terms
SHSE:603351 vs ZTS: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Well Pharmaceutical Group Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Well Pharmaceutical Group Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanjing Well Pharmaceutical Group Co's GF Score distribution charts can be found below:
* The bar in red indicates where Nanjing Well Pharmaceutical Group Co's GF Score falls into.
Nanjing Well Pharmaceutical Group Co (SHSE:603351) has a GF Score of 81 as of Aug. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nanjing Well Pharmaceutical Group Co and its competitors. This is 19% above median its historical median of 68.00. Over the past decade, Nanjing Well Pharmaceutical Group Co's GF Score has ranged from 16.00 to 83.00.
Is Nanjing Well Pharmaceutical Group Co's GF Score too high?
Nanjing Well Pharmaceutical Group Co's current GF Score of 81 is 19% above median its 10-year median of 68.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 83.00. Overall, Nanjing Well Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Well Pharmaceutical Group Co's GF Score compare to ZTS?
Nanjing Well Pharmaceutical Group Co's GF Score of 81 can be compared against companies in the Drug Manufacturers industry. Historically, Nanjing Well Pharmaceutical Group Co's own GF Score has ranged from 16.00 to 83.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nanjing Well Pharmaceutical Group Co and its competitors. Nanjing Well Pharmaceutical Group Co's current GF Score is 81, which is 19% above median its own 10-year median of 68.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Well Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Well Pharmaceutical Group Co (SHSE:603351) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.01, compared to a current price of ¥26.93 — trading 3.9% below its estimated fair value. The current GF Score is 81, which is 19% above median its 10-year median of 68.00. Nanjing Well Pharmaceutical Group Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Nanjing Well Pharmaceutical Group Co (SHSE:603351), the current GF Score is 81 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Well Pharmaceutical Group Co (SHSE:603351) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Well Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥26.93 is trading 3.9% below its estimated GF Value™ of ¥28.01.
GuruFocus considers Nanjing Well Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603351:
GF Score: 81 (19% above median its 10-year median of 68.00)
GF Value™: ¥28.01 vs. price of ¥26.93 (3.9% below fair value)
No single metric tells the full story. See the SHSE:603351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Well Pharmaceutical Group Co Ltd is engaged in research and development, production and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil and other products. The company uses a variety of pharmaceutical dosage forms such as injection, oral administration and external use to guarantee the molding, effectiveness, stability and safety of pharmaceutical dosage forms.
81GF Score
Get the complete analysis for SHSE:603351
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603351 has been successfully added to your 
